The Spanish blood management company was founded in 1940 in Barceloby Dr. José Grifols Roig, a hematologist and scientist, who was the first researcher to publish the plasmapheresis procedure in 1951. In June 2011, Grifols closed the $4 billion buyout of Talecris Biotherapeutics; in 2013 it acquired the Novartis blood transfusion diagnostics unit.
Grifols agrees to acquire a 517,000 sq ft plot of land to expand its production facilities in Barcelona, Spain. FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood Supply Under an IND Study Protocol. Grifols confirms that it has voluntarily signed the EFPIA Code of Conduct. Grifols will invest USD 360M to expand its manufacturing capacities for plasma-derived therapies. Grifols invests in the project led by AlbaJuna Therapeutics, a spin-off from IrsiCaixa, to fund the development of therapeutic antibodies against HIV. Grifols Obtains Exclusive Rights to Market and Distribute MassBiologics' Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine in U.S. Grifols agrees long term loan with the European Investment Bank. Grifols official opening of the Bioscience Division new worldwide operations facility in Ireland. Grifols to make a major equity investment in Alkahest. Grifols PhocusRx Certified DIACAP Compliant. Grifols partners with Johnston County educators to develop science program. Grifols receives FDA approval for its new purification plant to produce Gamunex in Los Angeles.
|Key Personnel: Víctor Grifols Roura, co-CEO; Victor Grifols Deu, co-CEO; Ramón Riera Roca, EVP, president, global commercial division; Alfredo Arroyo Guerra, corporate VP, CFO; Carlos Roura Fernandez, chief industrial officer; Montserrat Lloveras Calvo, corporate VP, director, corporate accounting & reporting; Vicente Blanquer Torre, corporate VP, quality & R&D; Mateo Florencio Borras Humbert, corporate VP, director, global HR; Francisco Javier Jorba Ribes, corporate VP, president, biological industrial group; Gregory Gene Rich, corporate VP, president & CEO Grifols Shared Services North America; David Ian Bell, corporate VP, GC, Grifols Shared Services North America; Nuria Pascual Lapena, corporate VP, treasury, risk management & IRO; Shinji Wada, corporate VP, president, plasma operations, Grifols Shared Services North America; Lafmin Morgan, president, bioscience & hospital division, Carsten Schroeder, president, diagnostic division.;|
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan
Sant Cugat del Vallès, Barcelona